Original Article

Neutrophil-to-lymphocyte ratio predicts heart failure readmissions and outcomes in patients undergoing transcatheter aortic valve replacement

Charl Khalil a,1, Michael Pham a,1, Abhishek C. Sawant a, Everett Sinibaldi a, Aishwarya Bhardwaja, Tharmathai Ramanana, Reema Qureshib, Sahoor Khana, Amira Ibrahima, Smitha N. Gowdaa, Alexander Pomakov, Priya Sadawartec, Ankush Lahotia, Rosemary Hansen b, Shannon Baldoa, Gerald Colerna, Ashish Pershad d, Vijay Iyera,*

a Division of Cardiology, State University of New York at Buffalo, Buffalo, NY, USA
b Dept of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA
c Division of Anesthesiology, NKPSIMS, Nagpur, India
d Division of Interventional Cardiology, Banner University Medical Center, Phoenix, AZ, USA

ARTICLE INFO

Article history:
Received 10 May 2018
Accepted 1 August 2018
Available online 17 August 2018

Keywords:
Heart failure
MACE
Mortality
NLR
Readmissions
TAVR

ABSTRACT

Objective: Neutrophil-to-lymphocyte ratio (NLR) has prognostic value in acute coronary syndromes. We investigated its utility for predicting heart failure (HF) admissions and major adverse cardiac outcomes in patients undergoing transcatheter aortic valve replacement (TAVR).

Methods: Data on clinical, laboratory, procedural, HF admissions, and major adverse cardiac events (MACEs) (all-cause mortality, recurrence of myocardial infarction requiring intervention, stroke) for 298 consecutive patients who underwent TAVR between 2012 and 2016 in our tertiary center were collected. Receiver-operating curve analysis identified a cutoff value of NLR of 4.0 for MACE after TAVR and sensitivity of 68% and specificity of 68% [area under the curve (AUC) = 0.65 [95% confidence interval (CI): 0.51–0.79], p = 0.03]. An NLR of 4.0 for HF hospitalizations after TAVR and sensitivity of 60% and specificity of 57% [AUC = 0.61 (95% CI: 0.53–0.69), p = 0.01]. NLR >4.0 before TAVR significantly predicted MACE after TAVR (68.4% vs. 31.6%, p = 0.02) and HF hospitalizations (58.3% vs. 41.7%, p = 0.03). NLR with TAVR risk score increased the predictive value for MACE after TAVR from AUC = 0.61 (95% CI: 0.50–0.72, p = 0.06) to AUC = 0.69 (95% CI: 0.57–0.80, p = 0.007).

Conclusion: NLR predicts all-cause mortality, MACE, and HF hospitalization 1 year after TAVR. NLR with TAVR risk score improved predictability for MACE. Further studies for prognostication using NLR are warranted.

© 2018 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Inflammation plays an integral role in the pathogenesis of atherosclerotic cardiovascular disease and calcific valvular heart disease. Inflammation causes activation of valvular endothelial cells with subendothelial lipid deposition and infiltration with monocytes transforming into macrophages. Ultimately, the combination of oxidized lipids, angiotensin II, and macrophages promote activation of the inflammatory cascade responsible for matrix remodeling, valvular fibrosis, and eventually calcification.1,2

Transcatheter aortic valve replacement (TAVR) is a well-established procedure for the treatment of severe aortic stenosis (AS) in intermediate- to high-risk patients who are poor candidates for surgical valve replacement.3,4 Owing to the global uptrend in the utilization of TAVR, there is an increasing need for improved
risk stratification of patients undergoing the procedure. Neutrophil-to-lymphocyte ratio (NLR) is a noninvasive, inexpensive, and widely available hematologic marker of inflammation.\textsuperscript{1} It has been studied as a prognostic marker in patients with severe calcific stenosis\textsuperscript{2–6} and heart failure (HF).\textsuperscript{7,8}

Post-TAVR hospitalizations are associated with increased rates of mortality and constitute a significant cost burden to the healthcare system. There is a growing body of research to identify causes and predictors of HF admissions after TAVR.\textsuperscript{9–11} To date, the role of NLR as a prognostic factor in predicting long-term outcomes after TAVR, including HF readmissions, remains to be determined. The goal of our study is four-fold: (1) to determine if NLR is associated with increased risk of major adverse cardiac events (MACE); (2) to determine if NLR is associated with increased risk of HF readmissions; (3) to determine if NLR is an independent predictor for short-term (30 days) and long-term (1 year) mortality in patients undergoing TAVR; and (4) to determine if NLR can be utilized for risk stratification of patients undergoing TAVR.

2. Methods

2.1. Study population

Our study is a retrospective review of a prospectively collected database. The study population comprised patients ($n = 610$) who were enrolled in the prospective TAVR registry of patients undergoing TAVR from January 2012 to July 2016 at our tertiary care center (Gates Vascular Institute, Buffalo, NY). Out of those, 141 patients did not have baseline echocardiographic variables, and 109 patients did not have baseline laboratory data pertaining to our study available for review. In addition, 42 patients were who had active malignancy or chronic inflammatory diseases were excluded. Finally, 20 patients who were lost to follow-up were excluded from the study. The remainder ($n = 298$) formed the study group and were included in the final analysis. All data variables were collected according to the standardized definitions adherent with the standards of the Society of Thoracic Surgeons (STS) and American College of Cardiology’s National Transcatheter Valve Therapy registry.

2.2. Clinical characteristics

Patient demographics and baseline characteristics including relevant clinical variables, such as medical comorbidities, were collected. In addition, use of home medications, specifically, diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and potassium-sparing diuretics was reviewed and recorded. Pre-TAVR noninvasive testing data including routine electrocardiogram and echo-cardiogram variables were collected. Pre-TAVR laboratory data including complete blood count (CBC), complete metabolic panel, and brain natriuretic peptide (BNP) were collected. In addition, data on MACE (all-cause mortality, recurrence of myocardial infarction [MI] requiring percutaneous coronary intervention [PCI] or stroke) and HF admissions 1 year after TAVR were collected.

2.3. Neutrophil-lymphocyte ratio

All study participants underwent pre-TAVR laboratory data testing including CBC. Blood sampling was performed in the TAVR clinic 1–3 weeks before the procedure. Patients whose CBC included differential counts were analyzed specifically. A CBC with five-part differential was measured using Coulter LH 750 Hematology Analyzer. Neutrophil and lymphocyte values were reported in standard international units and cell count $\times 10^9/L$. Receiver-operating curve (ROC) analysis of NLR identified the NLR cutoff value of the highest accuracy for our primary end points.

2.4. TAVR risk score

TAVR risk score was calculated after incorporating the following variables: age, sex, race, serum creatinine (mg/dl) on the same blood sample from which NLR was calculated, procedural access site, dialysis dependence, presence of the New York Heart Association class IV symptoms within 2 weeks of TAVR, and presence of severe chronic lung disease. The following variables were also included to assess the acuity of TAVR: procedural status (elective vs. urgent vs. emergency vs. salvage), prior cardiac arrest or cardiogenic shock, preprocedure inotrope use, and use of any mechanical assist device.

2.5. Outcomes assessment

The primary end points of this study were in-hospital mortality and MACEs (defined as death from all cause, recurrence of MI requiring PCI, or stroke) at 1 year. The U.S. Social Security Death Index and New York State Death Index records and patient electronic medical records were reviewed to obtain mortality data. The secondary outcome of our study was HF readmissions 1 year after TAVR. HF readmission was defined using the standard definitions of the Multi-Ethnic Study of Atherosclerosis study.\textsuperscript{15,12} The University at Buffalo Institutional Review Board approved all procedures with a waiver of individual informed consent. The study conforms to widely accepted ethical principles guiding human research.

2.6. Statistical analysis

The categorical variables were described as frequency (%) and were compared using either chi-square tests of independence or Fishers exact test as appropriate. Continuous variables were summarized as mean $\pm$ standard deviation for normally distributed data and medians with interquartile range (IQR) if the data were skewed. Continuous variables were compared across groups using a two-sample/paired $t$-test or Mann–Whitney $U$ test, as appropriate. ROCs were used to determine the area under the curve (AUC), and Kaplan–Meier survival analysis was used to evaluate freedom from MACE and HF readmissions. Statistical analysis was performed using STATA v13.0 (StataCorp, College Station, Texas). A p-value of $<0.05$ was considered significant.

3. Results

3.1. Study population

The baseline demographic and clinical characteristics of all patients ($n = 298$) are outlined in Table 1. The mean age among all patients was 83 $\pm$ 8 years, 51% were males, and 95% were Caucasians. The median STS risk score was 9.0 (IQR: 6.3–11.8). Ninety-four percent had hypertension; 43%, atrial fibrillation; 41%, peripheral arterial disease, and 36%, diabetes. Among all patients, diuretic use was 65%; beta-blocker, 68%; ACEi, 24%; ARB, 17%; and potassium-sparing diuretic, 7%.

3.2. NLR and MACE

Among all patients, there were 19 (7.2%) patients who experienced a MACE at 1 year after TAVR. As shown in Fig. 1, ROC analysis identified a cutoff value of NLR = 4.0 for MACE after TAVR with a sensitivity of 68% and specificity of 68% [AUC = 0.65 (95% CI: 0.51–0.79), $p = 0.03$]. In an unadjusted analysis, patients with NLR
4.0 before TAVR were significantly more likely to experience MACE after TAVR (68.4% vs. 31.6%, \( p = 0.02 \)). Next, we adjusted for STS risk score in a Cox proportional model after confirming that the assumptions of Cox model were met. As shown in Fig. 2, survival from MACE was significantly worse among patients with NLR >4.0 before TAVR than those with NLR <4.0 [hazard ratio (HR) = 2.72 (95% CI: 1.02–7.23), \( p = 0.04 \)].

### 3.3. NLR and HF readmissions

Among all patients who underwent TAVR, there were 48 (16.4%) patients who required hospitalization for HF. Patients with NLR >4.0 before TAVR had higher BNP levels during follow-up without significant difference in left ventricular ejection fraction compared to those with NLR <4.0, as shown in Table 2. As shown in Fig. 3, ROC analysis identified a cutoff value of NLR = 4.0 for HF hospitalizations after TAVR with a sensitivity of 60% and specificity of 57% [AUC = 0.61 (95% CI: 0.53–0.69), \( p = 0.01 \)]. In an unadjusted analysis, patients with NLR >4.0 before TAVR had a significantly higher risk of HF hospitalizations compared to those with NLR <4.0 (58.3% vs. 41.7%, \( p = 0.03 \)). Next, we performed an age-adjusted analysis for preprocedural BNP levels using a Cox proportional model after confirming the assumptions of Cox model were met. As shown in Fig. 4, patients with NLR >4.0 before TAVR had significantly worse survival from HF readmissions [HR = 1.9 (95% CI: 1.02–3.39), \( p = 0.04 \)].

### Table 1

| Variables                        | NLR <4.0 (n = 168) | NLR ≥ 4.0 (n = 130) | \( p \) value |
|----------------------------------|--------------------|---------------------|---------------|
| **Demographics**                 |                    |                     |               |
| Sex (male)                       | 81 (55%)           | 67 (45%)            | 0.57          |
| Age at procedure                 | 82 ± 8             | 83 ± 8              | 0.34          |
| Race (white)                     | 158 (94%)          | 123 (95%)           | 0.83          |
| **Risk factors**                 |                    |                     |               |
| Smoker                           | 6 (4%)             | 1 (0.8%)            | 0.14          |
| Diabetes                         | 52 (31%)           | 53 (41%)            | 0.08          |
| Hypertension                     | 159 (95%)          | 121 (93%)           | 0.57          |
| Systolic heart failure           | 44 (27%)           | 38 (30%)            | 0.59          |
| Periarticular vascular disease   | 67 (40%)           | 53 (41%)            | 0.88          |
| STS risk score                   | 8.6 (6.0–11.2)     | 9.5 (6.5–12.8)      | 0.08          |
| Prior myocardial infarction      | 25 (15%)           | 26 (20%)            | 0.25          |
| Atrial fibrillation/flutter      | 72 (43%)           | 50 (39%)            | 0.44          |
| NYHA class (II or higher)        | 53 (33%)           | 42 (35%)            | 0.81          |
| Stroke history                   | 19 (11%)           | 10 (8%)             | 0.30          |
| **Baseline BNP**                 | 405 (174–838)      | 527 (241–1160)      | 0.05          |
| **Echocardiographic variables**  |                    |                     |               |
| Baseline LVEF (%)                | 53 ± 13            | 55 ± 14             | 0.29          |
| PAP (mmHg)                       | 31 ± 15            | 32 ± 14             | 0.6           |
| **Home medications**            |                    |                     |               |
| Diuretics                        | 104 (62%)          | 91 (70%)            | 0.15          |
| Beta-blockers                    | 115 (69%)          | 87 (67%)            | 0.78          |
| Calcium channel blockers         | 36 (21%)           | 29 (22%)            | 0.86          |
| Angiotensin-converting enzyme inhibitor | 45 (27%) | 31 (24%)            | 0.56          |
| Aldosterone receptor blockers    | 25 (15%)           | 25 (10%)            | 0.32          |
| Potassium-sparing diuretics      | 10 (6%)            | 13 (10%)            | 0.19          |

Values are expressed as mean ± standard deviation, median (interquartile range), N (%).

BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; NLR, neutrophil-to-lymphocyte ratio; NYHA, New York Heart Association; PAP, pulmonary artery pressure; STS, Society of Thoracic Surgeons.
Finally, we calculated the risk of mortality using the TAVR mortality risk calculator. As shown in Fig. 5A, ROC analysis demonstrated that TAVR risk score predicted MACE with $AUC = 0.61$ (95% CI: 0.50–0.72, $p = 0.06$). Next, we combined the TAVR mortality risk with NLR in which we assigned one point for NLR $>4.0$ before TAVR. After repeating ROC analysis, combining NLR with TAVR risk score increased the predictive value for occurrence of MACE after TAVR ($AUC = 0.69$ (95% CI: 0.57–0.80), $p = 0.007$).

### 4. Discussion

Our study showed that NLR has a prognostic value in the risk stratification of patients undergoing TAVR. The key findings were (1) NLR cutoff of 4 has the highest discriminatory capability to differentiate incidence of MACE or HF hospitalizations after TAVR. (2) Patients with pre-TAVR NLR $>4$ had a statistically significant higher incidence of MACEs within 1 year after TAVR. (3) Patients with pre-TAVR NLR $>4$ had a significantly higher incidence of HF readmissions within 1 year after TAVR. (4) Combining NLR $>4$ (as one point) to TAVR risk score increased the predictive value for MACE after TAVR.

In the PARTNER trials, approximately 25% of patients who had undergone TAVR were deceased at 1 year. Among those who survived, a number reported significant HF symptoms, poor quality of life, and functional limitation.4,13,14 As such, consensus exists that TAVR should be offered to patients who may derive morbidity and mortality benefit. Identifying such patients remains a current challenge.15 NLR is a useful assessment tool to predict cardiovascular outcomes in several studies.16 e19 A representative sample of the general population of the United States showed that the average value of NLR is 2.15; values were significantly higher in individuals with chronic inflammatory states, such as diabetes, heart disease, obesity, and smoking.20

### 4.1. Role of NLR in predicting MACE

In stable coronary artery disease and acute coronary syndrome, NLR is independently associated with mortality.15,17 A recent study showed that patients with left main disease or triple-vessel disease at NLR $\geq 3.39$ have significantly higher incidence of 2-year MACEs, including stroke.21 Furthermore, a meta-analysis of eight cohort studies demonstrated a higher NLR as a predictor of MACE in patients undergoing coronary angiography or revascularization.22 A large variation in NLR levels from baseline to time of hospital discharge correlated with worse 1-year outcomes after TAVR; specifically, hospital admissions and mortality.23 Interestingly, high NLR was independently associated with stroke incidence in a retrospective cohort study of over 24,000 adults.24 A greater than 2.5 times risk for in-hospital mortality was identified in nonatrial fibrillation ischemic stroke.25,26 Furthermore, a high NLR at approximately 1 year after stroke correlated with increased risk of recurrent ischemic stroke.27

### 4.2. Role of NLR as a prognostic marker in TAVR

In patients with AS, high NLR has been associated with AS severity and MACEs.5,6 These studies suggest the potential utility of NLR in identifying patients with AS who may require intervention. Our study demonstrates that preoperative NLR independently predicts MACE at 1 year after TAVR. In patients with AS, NLR predicted a twofold higher risk for MACE after TAVR. In addition,
In HF, the hypothalamic-pituitary axis is activated leading to increased cortisol production resulting in decrease in the relative concentration of lymphocytes. In HF, the hypothalamic-pituitary axis is activated leading to increased cortisol production resulting in decrease in the relative concentration of lymphocytes. Lymphopenia has also been associated with a poor prognosis in HF.

The value of NLR in prognostication of patients with HF has been previously studied. NLR was found to be associated with adverse outcomes, regardless of whether it is calculated at the time of hospitalization or during follow-up after index hospitalization. Admission NLR was found to serve as a prognostic indicator of mortality in patients with HF, predict poor functional capacity, and the need for transplant in patients with HF. The proposed mechanism for NLR as a prognostic marker in patients with HF remains consistent across studies. It is theorized to be two-pronged: firstly, inflammatory reactions are known to contribute to the development of HF; and secondly, inflammatory stimuli lead to the release of cytokines and proteolytic enzymes causing destruction of the myocardium and decreased left ventricular function. In HF, the hypothalamic–pituitary axis is activated leading to increased cortisol production resulting in decrease in the relative concentration of lymphocytes. Lymphopenia has also been associated with a poor prognosis in HF.

Currently, information is scarce in the literature regarding the association between NLR and post-TAVR hospitalization. Our study demonstrates that a higher NLR carries a significantly higher risk of HF hospitalizations after TAVR. In addition to assisting in informed decision-making, NLR can also serve to reduce national and global health-care expenditure costs by decreasing hospital readmissions.

### 4.3. Role of NLR in predicting HF hospitalizations

The value of NLR in prognostication of patients with HF has been previously studied. NLR was found to be associated with adverse outcomes, regardless of whether it is calculated at the time of hospitalization or during follow-up after index hospitalization. Admission NLR was found to serve as a prognostic indicator of mortality in patients with HF, predict poor functional capacity, and the need for transplant in patients with HF. The proposed mechanism for NLR as a prognostic marker in patients with HF remains consistent across studies. It is theorized to be two-pronged: firstly, inflammatory reactions are known to contribute to the development of HF; and secondly, inflammatory stimuli lead to the release of cytokines and proteolytic enzymes causing destruction of the myocardium and decreased left ventricular function. In HF, the hypothalamic–pituitary axis is activated leading to increased cortisol production resulting in decrease in the relative concentration of lymphocytes. Lymphopenia has also been associated with a poor prognosis in HF.

Currently, information is scarce in the literature regarding the association between NLR and post-TAVR hospitalization. Our study demonstrates that a higher NLR carries a significantly higher risk of HF hospitalizations after TAVR. In addition to assisting in informed decision-making, NLR can also serve to reduce national and global health-care expenditure costs by decreasing hospital readmissions.

### 4.4. Incremental value of NLR when combined with TAVR risk score

The TAVR risk score represents a validated tool for the prediction of in-hospital mortality for the unique population undergoing TAVR. Currently, it stands as a reliable predictor of in-hospital mortality and is used in conjunction with a history, physical examination, laboratory data, and clinical judgment to stratify patients. It also provides objective insight into center- and patient-specific outcomes. Of note, limitations include acute mortality prognostication, and currently, the STS surgical aortic valve replacement (SAVR) model remains the most widely model used for 30-day mortality. Our study demonstrates that NLR can improve the predictability of MACE when combined with the TAVR risk score. This can help further risk stratify patients once they have been selected for a TAVR procedure even after considering the STS-patient-reported outcome measure (PROM) score. Patients who are less likely to benefit and more likely to have MACE may opt to forego TAVR.

### 4.5. Study limitations

Our study is a single-center experience, and the results may not be representative of the general population. However, our patient population had equal representation of both sexes, which is uncommon in cardiovascular research. NLR is a nonspecific inflammatory marker that could be affected by various inflammatory conditions. Hence, we excluded patients with chronic inflammatory conditions, history of malignancy, and those on steroid therapy from our study population to minimize possible confounding factors. Although we have adjusted for the majority of factors associated with increased risk of 1-year mortality, MACE, and HF hospitalizations, additional variables that are not routinely measured could potentially confound the results. Patients lost to follow-up and excluded may potentially represent a different study population with better or worse clinical characteristics. In our study, NLR was obtained at one timepoint preoperatively. Postoperative NLR values at various time intervals might augment its prognostic value. Also, cutoff value of NLR with the highest discriminatory capability identified in our study is different than what was reported in prior studies. This points out the need to identify standardized cutoff levels for consistent application.

### 5. Conclusion

Our study demonstrates NLR as a potentially valuable tool in the prognostication of patients who undergo TAVR. NLR is independently associated with mortality and HF readmissions. The addition of NLR to TAVR risk score improved the predictability of MACE after TAVR. Future larger prospective studies to evaluate the role of NLR at 1 year after TAVR and its utility as a cost-effective screening tool.
in providing clinically significant data for risk stratification of patients who undergo TAVR patients when combined with other variables are warranted.

### Funding

This research did not receive any specific grant from any funding agencies in the public, commercial or not-for-profit sectors.

### Conflicts of interest

All authors have none to declare.

### References

1. Mahler GJ, Butcher JT. Inflammatory regulation of valvular remodeling: the good, the bad, and the ugly. *Int J Inflamm*. 2011;2011:721419.
2. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. *J Am Coll Cardiol*. 2012;60:1854–1863.
3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med*. 2016;374:1609–1620.
4. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2016;373:1597–1607.
5. Cho KL, Cho SH, Her AY, Singh GB, Shin ES. Prognostic utility of neutrophil-to-lymphocyte ratio on adverse clinical outcomes in patients with severe calcific aortic stenosis. *PLoS One*. 2016;11:e0161530.
6. Avel A, Elsner A, Goksel A, et al. The relationship between neutrophil/lymphocyte ratio and calcific aortic stenosis. *Echocardiography*. 2014;31:1031–1035.
7. Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, Starling RC, Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. *Am J Cardiol*. 2015;115:57–61.
8. Uthamalingam S, Patwardhan EA, Subramanian S, et al. Utility of the neutrophil-to-lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. *Am J Cardiol*. 2011;107:433–438.
9. Durand E, Doutriaux M, Bettinger N, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. *JACC Cardiovasc Interv*. 2017;10:2426–2436.
10. Nombela-Franco L, del Trigo M, Taitano-Polo G, et al. Incidence, causes, and predictors of early (<30 days) and late unplanned hospital readmissions after transcatheter aortic valve replacement. *JACC Cardiovasc Interv*. 2015;8:1748–1757.
11. Kolte D, Khera S, Sardar MR, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the United States: insights from the nationwide readmissions database. *Circ Cardiovasc Interv*. 2015;8:1758–1767.
12. Bhardwaj A, Ramanan T, Khalil C, et al. Valvulopathic impedance predicts heart failure readmissions in patients undergoing transcatheter aortic valve replacement. *Structural Heart*. 2017;1:277–284.
13. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcathetet aortic valve replacement in inoperable patients with severe aortic stenosis. *Circulation*. 2011;124:1964–1972.
14. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. 2011;364:2187–2198.
15. Mack MJ, Holper EM. TAVR risk assessment: does the eyeball test have 20/20 vision, or can we do better? *J Am Coll Cardiol*. 2016;68:353–355.
16. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cacci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. *Clin Chim Acta*. 2008;395:27–31.
17. Azab B, Zaker M, Weisberg FX, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. *Am J Cardiol*. 2010;106:470–476.
18. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow in in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. *Am J Cardiol*. 2012;110:621–627.
19. Tokgoz S, Kayrak M, Akpinar Z, Seyithanoglu A, Guney F, Yurutek B. Neutrophil lymphocyte ratio as a predictor of stroke. *J Stroke Cerebrovasc Dis*. 2013;22:1169–1174.
20. Azab B, Camacho-Rivera M, Taioi E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. *PLoS One*. 2014;9:e112361.
21. Xu N, Tang XF, Yao Y, et al. Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction. *Catheter Cardiovasc Interv*. 2018;91(1):551–557.
22. Wang X, Zhang G, Jiang X, Zhu H, Li Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014;234:206–213.
23. Condado JF, Junpaparp B, Binongho JN, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can risk stratify patients in transcatheter aortic-valve replacement (TAVR). *Int J Cardiol*. 2016;223:444–449.
24. Sab B, Shin DW, Kwon HM, et al. Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults. *PLoS One*. 2017;12:e0183706.
25. Ertas G, Sonmez O, Turfan M, et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. *J Neurol*. 2013;234:49–52.
26. Fang YN, Tong MS, Sungh PH, et al. Higher neutrophil counts and neutrophil-to-lymphocyte ratio predict prognostic outcomes in patients after non-atrial fibrillation-induced ischemic stroke. *Biomed J*. 2017;40:154–162.
27. Xue J, Huang W, Chen X, et al. Neutrophil-to-lymphocyte ratio is a prognostic marker in acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2017;26:650–657.
28. Yan W, Li RJ, Qa J, Mu Y, Liu CL, He KL. Neutrophil-to-lymphocyte ratio compared to N-terminal pro-brain natriuretic peptide as a prognostic marker of adverse events in elderly patients with chronic heart failure. *J Geriatr Cardiol*. 2017;14:127–134.
29. Yu C, Chen M, Chen Z, Lu G. Predictive and prognostic value of admission neutrophil-to-lymphocyte ratio in patients with CHD. *Herz*. 2016;41:605–613.
30. Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. *Arg Bras Cardiol*. 2015;105:560–583.
31. Turfan M, Erdogan E, Tasal A, et al. Neutrophil-to-lymphocyte ratio and in-hospital mortality in patients with acute heart failure. *Clinics (Sao Paulo)*. 2014;69:190–193.
32. Cakici M, Cetin M, Dogan A, et al. Neutrophil to lymphocyte ratio predicts poor functional capacity in patients with heart failure. *Tark Kardiyoj Demegi Arvsi*. 2014;4:612–620.
33. Yndestad A, Damas JR, Ose E, Ueland T, Gulsetad L, Aukrust P. Systemic inflammation in heart failure—the whys and wherefores. *Heart Fail Rev*. 2006;11:83–92.
34. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart*. 2004;90:464–470.
35. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. *Chest*. 1994;105:897–904.
36. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation*. 1996;93:1201–1206.
37. Maisel AS, Knowlton KU, Fowler P, et al. Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. *J Clin Invest*. 1990;85:462–467.
38. Onnen SR, Hodge DO, Rodeheffer RJ, McGregor GG, Thomson SP, Gibbons RJ. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. *Circulation*. 1998;97:19–22.
39. Rother RC, Burchhardt OA, Harpes P, Muller-Steinhardt F, Pollath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. *Am J Emerg Med*. 2006;24:451–454.
40. Edwards FH, Cohen DJ, O’Brien SM, et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. *JAMA Cardiol*. 2016;1:46–52.